Panacea Biotec has entered into a joint collaboration with Bion Pharma. In an interview to CNBC-TV18, Rajesh Jain, Joint MD of Panacea Biotech spoke about the latest happenings in his company and sector.
Bion Pharma is one of Panacea Biotech’s distributors in US and are already distributing two products on the market manufactured by Panacea.
This joint collaboration to develop seven complex generics is an addition to the existing products that they are selling on the US market, he said.
These products are based on the principles that both the partners will put in their money and develop these products and register. Panacea is responsible for developing these complex molecules into formulation, manufacturing it, getting them registered in US and Bion will ensure that they distribute these products and generate revenues.
“We are expecting that six of these dossiers will be filed in CY18 and we expect that they will be launched in US market somewhere around 2019. They will start contributing in a significant manner to Panacea’s US business,” he added.
All these seven dossiers belong to immunosuppressive category and are given to organ transplant patients to prevent organ rejection.
He does not expect any unusual risk in the development of drugs and is sure that nine out of ten of these products would reach the market, he mentioned.
We are the number one company selling all these complex generics in immunosuppressive therapies and in organ transplantation. We have established reputation in the market over the last one decade of successfully bringing these products to different markets starting from India and several other markets, said Jain.
The company is confident of putting these products in the US market going forward.For full interview, watch accompanying video...